Latest Regulatory News

Tempest Minerals has agreed to acquire a 145km² advanced gold portfolio in New Zealand’s North Island, unlocking multiple drill-ready targets in a prolific gold province. The $2 million all-scrip deal includes performance milestones tied to exploration success.

Paterson Resources has responded to an ASX price query following a notable rise in its share price and trading volume, confirming no undisclosed information is driving the recent market activity.

Prospect Resources is set to increase its ownership in the Mumbezhi Copper Project to 90%, following a US$4.25 million acquisition. The company plans to kick off an ambitious Phase 3 drilling program in early Q2 2026, backed by a recent A$45 million equity raise.

Stellar Resources has uncovered a new high-grade tin lode 60 meters beneath its existing Severn deposit, setting the stage for a resource upgrade and advancing its Heemskirk Tin Project development.

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.

Provaris Energy has successfully raised $1.325 million through an oversubscribed placement, aiming to advance its 2026 development milestones in hydrogen and carbon dioxide storage technologies.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

The Lottery Corporation is reshaping its executive team and operating model to sharpen focus on digital expansion and local market growth, effective July 2026.

Magellan Financial Group has applied for quotation of over 15 million new shares following a recent transaction, alongside announcing a $20 million Share Purchase Plan targeting further capital raising.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Bapcor Limited has initiated a fully underwritten $200 million equity raising at $0.60 per share, aiming to reduce debt and support a strategic turnaround under new leadership. The retail entitlement offer opened on 5 March and closes on 19 March 2026.

dorsaVi has formed a world-class Technical Advisory Board to accelerate its pioneering ‘Intelligence at the Ultra Edge’ strategy, integrating advanced memory and neuromorphic computing into robotics and healthcare devices.